Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b Study of BPZE1 Intranasal Pertussis Vaccine in Adults to Assess Immunological Response and Safety Profile of 1-Dose (Prime) and 2-Doses (Prime+Boost) Schedule, Compared to a Boostrix™ Prime Dose With or Without a BPZE1 Boost Dose

NCT03942406 is registered in ClinicalTrials.gov with ILiAD Biotechnologies as lead sponsor.

NCT NCT03942406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03942406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b Study of BPZE1 Intranasal Pertussis Vaccine in Adults to Assess Immunological Response and Safety Profile of 1-Dose (Prime) and 2-Doses (Prime+Boost) Schedule, Compared to a Boostrix™ Prime Dose With or Without a BPZE1 Boost Dose
Lead sponsor
ILiAD Biotechnologies
Phase
Phase 2
Overall status
Completed
Start date
June 15, 2019
Completion date
June 24, 2020
Enrollment
300 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pertussis, whooping cough